Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06746831 · ClinicalTrials.gov registry record · Phase 1
Methamphetamine Isomer Pharmacology in Humans
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Not yet
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT06746831 is a Phase 1 study that has not yet begun recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 17 participants.
The verdict
NCT06746831, a Phase 1 study, has not yet begun recruiting, sponsored by University of Wisconsin, Madison.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.
Interventions
- DRUG S-(+)-methamphetamine
- DRUG R-(-)-methamphetamine
- DRUG 1:1 racemic mixture of two isomers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06746831
The ClinicalTrials.gov registry entry for NCT06746831 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which S-(+)-methamphetamine is the first listed.
NCT06746831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06746831 about?
NCT06746831 is a clinical study titled "Methamphetamine Isomer Pharmacology in Humans". This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (AD...
What is the current status of trial NCT06746831?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2026-07. Estimated completion is 2028-03.
What interventions are being tested in trial NCT06746831?
The interventions under investigation include: S-(+)-methamphetamine (DRUG), R-(-)-methamphetamine (DRUG), 1:1 racemic mixture of two isomers (DRUG).
Who is sponsoring clinical trial NCT06746831?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.